Baptist Health Herbert Wertheim Cancer Institute Treats Its 100th CAR T-Cell Therapy Patient - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Baptist Health Herbert Wertheim Cancer Institute Treats Its 100th CAR T-Cell Therapy Patient

  • By

  • November 16, 2026

  • 4 min

Share

Clinical Scorecard: Baptist Health Herbert Wertheim Cancer Institute Treats Its 100th CAR T-Cell Therapy Patient

At a Glance

CategoryDetail
ConditionCertain blood cancers
Key MechanismsA patient’s T cells are collected, genetically modified to help detect cancer cells, expanded in a laboratory, and infused after preparatory chemotherapy.
Target PopulationPatients with certain blood cancers; the article does not specify eligibility criteria.
Care SettingThe Institute describes onsite cell processing, dedicated inpatient bone marrow and immunotherapy programs, and coordination across evaluation, collection, administration, monitoring, and ongoing care.

Key Highlights

  • The Institute reports treating its 100th patient with CAR T-cell therapy.
  • The treatment uses a patient’s own T cells, genetically modified to help the immune system detect and eliminate cancer.
  • The Institute describes a specially equipped onsite laboratory certified as a Good Manufacturing Practice (GMP) facility.
  • The Blood and Marrow Stem Cell Transplant Program is accredited by the Foundation for the Accreditation of Cellular Therapy.
  • Hope Tower at Baptist Health Baptist Hospital houses the Institute’s inpatient bone marrow and immunotherapy programs.

Guideline-Based Recommendations

Diagnosis

  • The article does not provide diagnostic criteria or a diagnostic workup.

Management

  • The article describes T-cell collection, genetic modification and laboratory expansion, preparatory chemotherapy, and infusion of the modified cells.

Monitoring & Follow-up

  • The article mentions monitoring and ongoing care but does not specify protocols.

Risks

  • The article does not describe treatment risks or adverse effects.

Patient & Prescribing Data

Patients with certain blood cancers considered for CAR T-cell therapy; specific eligibility criteria are not provided.

CAR T-cell therapy uses the patient’s own modified T cells. The article does not provide dosing, product-specific prescribing information, or treatment outcomes.

Clinical Best Practices

  • The article describes coordination across patient evaluation, cell collection, administration, monitoring, and ongoing care.
  • The article describes preparatory chemotherapy before infusion of the modified T cells.
  • The program identifies collaboration among physicians, advanced practice providers, nurses, transplant coordinators, cellular therapy specialists, pharmacists, and clinical and support staff.

Related Resources & Content

    Original Source(s)

    Related Content